
Inferior mesenteric arteriovenous fistula during treatment with bevacizumab in colorectal cancer patient: A case report
Author(s) -
Ayako Doi,
Hiroyuki Takeda,
Kumiko Umemoto,
Ryosuke Oumi,
Shinji Wada,
Shingo Hamaguchi,
Hidefumi Mimura,
Hajime Arai,
Yoshiki Horie,
Takuro Mizukami,
Naoki Izawa,
Takashi Ogura,
Takako Eguchi Nakajima,
Yu Sunakawa
Publication year - 2020
Publication title -
world journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v12.i11.1364
Subject(s) - medicine , bevacizumab , colorectal cancer , surgery , chemotherapy , radiology , colonoscopy , embolization , fistula , cancer
Fistula formation is a severe adverse event related to antiangiogenetic agents such as bevacizumab and inferior mesenteric arteriovenous fistula (IMAVF) is a result of acquired factor, especially colon surgery. However, IMAVF occurs very rarely and there are few reports in patients during chemotherapy. We report a case of a patient who developed IMAVF during treatment with bevacizumab in metastatic colorectal cancer (mCRC) after colon surgery.